NCT02903004View on ClinicalTrials.gov

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

242

Participants

Timeline

Start Date

April 11, 2016

Primary Completion Date

December 20, 2018

Study Completion Date

December 20, 2018

Conditions

Ovarian Neoplasms

Interventions

DRUG

Trabectedin

DRUG

Pegylated Liposomal Doxorubicin

DRUG

Topotecan

DRUG

Gemcitabine

DRUG

Weekly Paclitaxel

DRUG

Carboplatin

Trial Locations (1)

00168

Domenica Lorusso, Rome

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT02903004 - Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | Biotech Hunter | Biotech Hunter